Emerging CBD Industry Tetrahydrocannabinol (“THC”) may be the most popular part of the cannabis plant for its psychoactive properties, but cannabidiol (“CBD”) has become the focus of a marijuana growing number of clinical studies. According to ProjectCBD, there are over 50 medical conditions where CBD has shown some promise in treating the underlying problems or alleviating symptoms, while many large pharmaceutical companies are engaging in new studies. The legal hemp-based CBD market is projected to reach between $2.1 billion by 2020, according to Hemp Business Journal. Unlike psychoactive THC, the Industrial Hemp Farming Act of 2015 excluded hemp from the Drug Enforcement Administration’s controlled substances list, which effectively legalized hemp-derived CBDs. Many other countries around the world have similarly permitted the importation of hemp-based CBD products. Safe Harbor This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law.